

## SUMMARY OF PRODUCT CHARACTERISTICS

### 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Quinoflox 100 mg/ml solution for injection for cattle and pigs

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each ml contains:

**Active substance:**

Enrofloxacin 100.0 mg

**Excipients:**

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzyl alcohol	0.02 ml
Lactic acid	
Disodium edetate	
Water for injections	

Clear yellow solution

### 3. CLINICAL INFORMATION

#### 3.1 Target species

Cattle and pigs.

#### 3.2 Indications for use for each target species

##### Cattle

Treatment of infections of the respiratory tract caused by *Mannheimia haemolytica*, *Mycoplasma* spp and *Pasteurella multocida*.

Treatment of infections of the alimentary tract caused by *Escherichia coli*.

Treatment of septicaemia caused by *Escherichia coli*.

Treatment of acute mycoplasma-associated arthritis due to *Mycoplasma bovis* in cattle less than 2 years old.

##### Pigs

Treatment of infections of the respiratory tract caused by *Actinobacillus pleuropneumoniae*, *Mycoplasma* spp. and *Pasteurella multocida* .

Treatment of infections of the urinary tract caused by *Escherichia coli*.

Treatment of post-partum dysgalactiae syndrome, PDS (MMA syndrome) caused by *Escherichia coli* and *Klebsiella* spp.

Treatment of infections of the alimentary tract caused by *Escherichia coli*.

Treatment of septicaemia caused by *Escherichia coli*.

### **3.3 Contraindications**

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in growing horses because of possible deleterious damage on articular cartilage.

Do not use in animals with central nervous system-associated seizure disorders.

### **3.4 Special warnings**

None.

### **3.5 Special precautions for use**

Special precautions for safe use in the target species:

Degenerative changes of articular cartilage were observed in calves treated orally with 30 mg enrofloxacin/kg bw during 14 days.

Do not use in the presence of existing disorders of cartilage development or musculoskeletal damage around functionally significant or weight-bearing joints.

The use of enrofloxacin in growing lambs at the recommended dose for 15 days caused histological changes in the articular cartilage, not associated with clinical signs.

Use of the product should be in accordance with official, national and regional antimicrobial policies.

Use of the product should be based on identification and susceptibility testing of the target pathogen(s). If this is not possible, therapy should be based on epidemiological information and knowledge of susceptibility of the target pathogens at farm level, or at local/regional level.

Fluoroquinolones should be reserved for the treatment of clinical conditions which have responded poorly, or are expected to respond poorly, to other classes of antimicrobials.

Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to the fluoroquinolones and may decrease the effectiveness of treatment with other quinolones due to the potential for cross resistance.

An antibiotic with a lower risk of antimicrobial resistance selection (lower AMEG category) should be used for first line treatment where susceptibility testing suggests the likely efficacy of this approach.

The feeding of waste milk containing residues of enrofloxacin to calves should be avoided up to the end of the milk withdrawal period (except during the colostrum

phase), because it could select antimicrobial-resistant bacteria within the intestinal microbiota of the calf and increase the faecal shedding of these bacteria.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

People with known hypersensitivity to fluoroquinolones should avoid contact with the veterinary medicinal product.

Direct contact with the skin should be avoided because of sensitisation, contact dermatitis and possible hypersensitivity reactions to fluoroquinolones.

Avoid skin and eye contact. Wash any splashes from skin or eyes immediately with water.

Wash hands after use. Do not eat, drink or smoke whilst handling the veterinary medicinal product.

Care should be taken to avoid accidental self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

In countries where feeding of fallen stock to scavenger bird populations is permitted as a conservation measure (see Commission Decision 2003/322/EC), the possible risk to hatching success should be considered before feeding carcasses of livestock recently treated with this veterinary medicinal product.

### 3.6 Adverse events

#### Cattle

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (e.g. diarrhoea) <sup>1</sup> , and Circulatory shock. <sup>2</sup>
--	---

<sup>1</sup> These signs are generally mild and transient.

<sup>2</sup> As a result of circulatory impairment following intravenous treatment.

#### Pigs

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Digestive tract disorders (e.g. diarrhoea) <sup>1</sup> , and Injection site reaction and Injection site inflammation. <sup>3</sup>
--	---

<sup>1</sup> These signs are generally mild and transient.

<sup>3</sup> After intramuscular administration. They may persist up to 28 days after the injection.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also section 16 of the package leaflet for respective contact details.

### **3.7 Use during pregnancy, lactation or lay**

#### **Cattle**

The safety of the veterinary medicinal product has been established in pregnant cows during the 1st quarter of pregnancy. The veterinary medicinal product can be used in pregnant cows during the 1st quarter of pregnancy.

The use of the veterinary medicinal product in cows during the 3 last quarters of pregnancy should be based on a benefit-risk assessment by the responsible veterinarian.

The veterinary medicinal product can be used in cows during lactation.

#### **Pigs**

The safety of the veterinary medicinal product has not been established during pregnancy. Use only accordingly to the benefit-risk assessment by the responsible veterinarian.

The veterinary medicinal product can be used in sows during lactation.

### **3.8 Interaction with other medicinal products and other forms of interaction**

Do not use enrofloxacin concomitantly with antimicrobial substances acting antagonistically to quinolones (e.g. macrolides, tetracyclines or phenicols).

Do not use concurrently with theophylline as the elimination of theophylline may be delayed.

### **3.9 Administration routes and dosage**

Intravenous, subcutaneous or intramuscular use.

Repeated injections should be made at different injection sites.

To ensure a correct dosage, body weight should be determined as accurately as possible.

#### **Cattle**

5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily for 3-5 days.

Acute mycoplasma-associated arthritis due to *Mycoplasma bovis* in cattle less than 2 years old: 5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily for 5 days.

The veterinary medicinal product can be administered by slow intravenous or subcutaneous administration.

Not more than 10 ml should be administered at one subcutaneous injection site.

#### **Pigs**

2.5 mg of enrofloxacin/kg bw, corresponding to 0.5 ml/20 kg bw, once daily by intramuscular injection for 3 days.

Alimentary tract infection or septicaemia caused by *Escherichia coli*: 5 mg of enrofloxacin/kg bw, corresponding to 1 ml/20 kg bw, once daily by intramuscular injection for 3 days.

In pigs, the injection should be made in the neck at the ear base.

Not more than 3 ml should be administered at one intramuscular injection site.

### **3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)**

In cases of accidental overdoses digestive tract disorders (e.g. vomiting, diarrhoea) and neurological disorders may occur.

In pigs, no adverse effects were reported after the administration of 5 times the recommended dose.

In cattle overdose has not been documented.

In accidental overdose there is no antidote and treatment should be symptomatic.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

#### **3.12 Withdrawal periods**

##### Cattle:

Following intravenous injection:

Meat and offal: 5 days.

Milk: 72 hours.

Following subcutaneous injection:

Meat and offal: 12 days.

Milk: 96 hours.

##### Pigs:

Meat and offal: 13 days.

## **4. PHARMACOLOGICAL INFORMATION**

### **4.1. ATCvet Code: QJ01MA90**

### **4.2. Pharmacodynamics**

#### Mode of action

Two enzymes essential in DNA replication and transcription, DNA gyrase and topoisomerase IV, have been identified as the molecular targets of fluoroquinolones. Target inhibition is caused by non-covalent binding of fluoroquinolone molecules to these enzymes. Replication forks and translational complexes cannot proceed beyond such enzyme-DNA-fluoroquinolone complexes, and inhibition of DNA and mRNA synthesis triggers events resulting in a rapid, drug

concentration-dependent killing of pathogenic bacteria. The mode of action of enrofloxacin is bactericidal and bactericidal activity is concentration dependent.

#### Antibacterial spectrum

Enrofloxacin is active against many Gram-negative bacteria such as *Escherichia coli*, *Klebsiella* spp., *Actinobacillus pleuropneumoniae*, *Mannheimia haemolytica*, *Pasteurella* spp. (e.g. *Pasteurella multocida*), against Gram-positive bacteria such as *Staphylococcus* spp. (e.g. *Staphylococcus aureus*) and against *Mycoplasma* spp. at the recommended therapeutic doses.

#### Types and mechanisms of resistance

Resistance to fluoroquinolones has been reported to arise from five sources, (i) point mutations in the genes encoding for DNA gyrase and/or topoisomerase IV leading to alterations of the respective enzyme, (ii) alterations of drug permeability in Gram-negative bacteria, (iii) efflux mechanisms, (iv) plasmid mediated resistance and (v) gyrase protecting proteins. All mechanisms lead to a reduced susceptibility of the bacteria to fluoroquinolones. Cross-resistance within the fluoroquinolone class of antimicrobials is common.

### **4.3. Pharmacokinetics**

Enrofloxacin is rapidly absorbed after parenteral injection. Bioavailability is high (approximately 100% in pig and cattle) with a low to moderate plasma protein binding (approximately 20 to 50%). Enrofloxacin is metabolised to the active substance ciprofloxacin at approximately 40% in ruminants and less than 10% in pigs.

Enrofloxacin and ciprofloxacin distribute well into all target tissues, e.g. lung, kidney, skin and liver, reaching 2- to 3-fold higher concentrations than in plasma. Parent substance and active metabolite are cleared from the body via urine and faeces.

Accumulation in plasma does not occur following a treatment interval of 24 h.

In milk, most of drug activity consists on ciprofloxacin. Overall drug concentrations peak at 2 hours after treatment showing an approximately 3-fold higher total exposure over the 24 hours dosing interval compared to plasma.

	Pigs	Pigs	Cattle	Cattle
Dose rate (mg/kg bw)	2.5	5	5	5
Route of administration	im	im	iv	sc
T <sub>max</sub> (h)	2	2	/	3.5
C <sub>max</sub> (µg/ml)	0.7	1.6	/	0.733
AUC (µg·h/ml)	6.6	15.9	9.8	5.9
Terminal half-life (h)	13.12	8.10	/	7.8
Elimination half-life (h)	7.73	7.73	2.3	
F (%)	95.6	/	/	88.2

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

### **5.2 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 3 years.  
Shelf life after first opening the immediate packaging: 28 days.

### **5.3 Special precautions for storage**

This veterinary medicinal product does not require any special temperature storage conditions.

Store in the original package in order to protect from light.

### **5.4 Nature and composition of immediate packaging**

Amber polypropylene vials of 50, 100 and 250 ml provided with a grey (50 ml and 100 ml) or pink (250 ml) rubber-butyl stopper and aluminium seal with a green Flip-Off sealing.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

## **6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Global Vet Health S.L.  
Calle Capcanes 12 Bajos  
Poligon Agro-Reus  
43206 Reus  
Spain

## **7. MARKETING AUTHORISATION NUMBER**

Vm 36167/3001

**8. DATE OF FIRST AUTHORISATION**

19 December 2012


**9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS**

March 2023

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary)..

A handwritten signature in black ink, consisting of several loops and a final horizontal stroke.

Approved: 16 March 2023